This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.
Subscribe to the Daily Journal for access to Daily Appellate Reports, Verdicts, Judicial Profiles and more...

Litigation

Mar. 29, 2016

Jury says Gilead Sciences must pay Merck & Co. $200 million for patent infringement

A federal jury on Thursday said bio-pharmaceutical company Gilead Sciences Inc. has to pay its competitor in the hepatitis C drug market $200 million in damages for infringing on two of Merck & Co.'s patents.

By Amanda Schallert
Daily Journal Staff Writer

A federal jury said bio-pharmaceutical company Gilead Sciences Inc. must pay $200 million in damages for infringing on two of its competitor Merck & Co.'s patents, after Gilead forged into the hepatitis C treatment market with blockbuster drugs before getting the legal go-ahead.

New Jersey-based Merck pharmaceuticals was seeking $2 billion in the Northern District case before Judge Jeffrey...

To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!

Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)

Already a subscriber?

Enewsletter Sign-up